The short version: The Wolverine stack combines BPC-157 and TB-500, two research peptides studied for tissue repair applications. Both are sold as research-use-only laboratory chemicals, not medications, and both were placed in FDA Category 2 of bulk drug substances that may present significant safety risks in 2023. No published study has evaluated the combination as a formulation. Before ordering, verify the supplier’s lot-specific certificate of analysis, confirm the testing laboratory is independent, and check that the listing maintains a strict research-use-only boundary. Alta Peptides publishes lot-specific certificates of analysis for its research-grade BPC-157 and TB-500, which is the baseline standard any researcher should expect before ordering.
Search for “wolverine peptide stack” and you will find a market built around a two-peptide combination that has become one of the most recognised stacks in the research peptide category. The name comes from a marketing convention rather than a scientific designation. The two components, BPC-157 and TB-500, have separate research histories and separate mechanisms of action.
This guide explains what the stack is, what the published literature says about each component, why the combination has not been studied as a formulation, and what documentation to verify before placing an order.
What the Wolverine stack is
The Wolverine stack is a fixed-ratio combination of two peptides: BPC-157 and TB-500. The most common configuration is a 20mg total vial containing 10mg of BPC-157 and 10mg of TB-500, though other ratios are also sold. The blend is supplied as a lyophilised powder labelled for laboratory research use only.
The two components are often discussed together because they are studied for overlapping applications in tissue repair, but they operate through different mechanisms. The Alta Peptides guide to the Wolverine stack explains the rationale behind the combination and the documentation standards that apply.
The individual components: what the research shows
BPC-157: preclinical evidence, no human trials for this indication
BPC-157 is a synthetic pentadecapeptide derived from human gastric juice protein. A review published in Cell and Tissue Research in 2019 examined BPC-157’s role in accelerating musculoskeletal soft tissue healing. The review found that BPC-157 was studied extensively in animal models for tendon, ligament, and muscle repair, but noted that human clinical trial data is lacking.
USADA’s athlete guidance on BPC-157 states plainly that there are no human clinical trials establishing efficacy for any diagnosis or treatment, and that because the compound has not been extensively studied in humans, it is unknown whether there is a safe dose. The FDA has placed BPC-157 in Category 2 of bulk drug substances that may present significant safety risks when used in compounding.
TB-500: actin regulation and cell migration research
TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring peptide involved in actin regulation and cell migration. A study published in the Annals of the New York Academy of Sciences describes thymosin beta-4 as an actin-sequestering protein that is upregulated in response to tissue injury and plays a role in cell migration and tissue repair.
A study published in the FASEB Journal examined the role of thymosin beta-4 in cell migration and tissue repair. The researchers found that thymosin beta-4 promotes cell migration by regulating actin dynamics, and that the peptide is upregulated in response to tissue injury. The study concluded that thymosin beta-4 plays a critical role in wound healing, though the research was limited to in-vitro and animal models.
TB-500 is prohibited at all times under the World Anti-Doping Agency’s Prohibited List. USADA’s sanction announcement for triathlete Anthony McCauley stated that McCauley accepted a four-year suspension after testing positive for BPC-157, TB-500, CJC-1295, and ipamorelin.
Why the combination has not been studied
The most important limitation of the Wolverine stack is also the simplest to state: no published study has evaluated the two-peptide combination as a formulation. This means that the interaction between the two peptides, their combined stability in a single lyophilised vial, and their combined effects in any biological system are all unknown from a published-evidence perspective.
The Alta Peptides recovery and repair category lists the products studied in this context and the documentation that accompanies each. The company’s certificates page collects the lot-specific reports for all products.
For researchers, the practical implication is that the Wolverine stack is a novel formulation in the research sense. Any experiment using it is testing a combination that has not been characterised in the published literature.
Video: The truth about the Wolverine stack
This third-party video provides general context on the Wolverine stack. It is not affiliated with Alta Peptides and is not a substitute for laboratory documentation or the published literature.
The researcher’s verification checklist
1. Lot-specific certificate of analysis for the blend
A certificate of analysis (COA) is only meaningful if it corresponds to the exact lot you are buying. For a blend, this is more complicated than for a single peptide. The COA should confirm the identity and quantity of each component in the blend, not just the total peptide content.
2. Component-specific identity results
A certificate for a peptide blend should include identity confirmation for each component. For the Wolverine stack specifically, the identity confirmation should establish that both peptides are present and match their reference standards.
3. The research-use-only boundary
The RUO label means the product is not intended for diagnostic, therapeutic, or human use. What to watch for is a supplier that uses the RUO label while simultaneously publishing dosing information, before-and-after photos, or customer testimonials about human use.
4. Evidence disclosure
A trustworthy supplier discloses the limits of the evidence for a product. For the Wolverine stack, that means stating clearly that the components are studied separately and that the combination is unstudied.
How Alta Peptides approaches Wolverine stack documentation
Alta Peptides is a UK-based research peptide supplier that publishes lot-specific documentation for each product configuration. The growth hormone category lists the peptides studied in related contexts and the documentation that accompanies each.
The Alta Peptides comparison of oral and injectable BPC-157 explains the differences between the two routes and why researchers need to be precise about which route a given study used.
Comparing the Wolverine components
| Component | Origin | Primary research interest | Human evidence |
|---|---|---|---|
| BPC-157 | Gastric juice protein fragment | Angiogenesis, tissue repair | Preclinical only |
| TB-500 | Thymosin beta-4 fragment | Cell migration, actin regulation | Preclinical only |
| Wolverine stack | Combination of the above | Tissue repair research | No combination studies |
Common questions about the Wolverine stack
What is the Wolverine stack made of?
The Wolverine stack combines two peptides: BPC-157 and TB-500. The most common configuration is a 20mg vial containing 10mg of BPC-157 and 10mg of TB-500. The blend is sold as a research-use-only laboratory chemical.
Has the Wolverine stack been studied in clinical trials?
No. No published study has evaluated the two-peptide combination as a formulation. The individual components have separate research histories, but the blend itself has not been tested in clinical trials.
What purity should a Wolverine stack COA show?
Purity by HPLC above 95 percent is the typical threshold for research-grade peptides. The purity figure is only meaningful alongside identity and content results. For a blend, the identity confirmation should establish that both peptides are present and match their reference standards.
How do I verify that a Wolverine stack COA is real?
Check that the testing laboratory is named and that the report ID can be cross-referenced. Some laboratories publish verification portals where a report ID can be entered to confirm the document’s authenticity.
What is the difference between the Wolverine stack and the GLOW blend?
The Wolverine stack contains BPC-157 and TB-500. The GLOW blend contains GHK-Cu in addition to BPC-157 and TB-500. The naming reflects the components included. Researchers should confirm the identity of any product by its COA, not by the brand name on the vial.
What should I do if a supplier’s listing makes health claims?
Treat it as a disqualifying signal. Health claims on a research peptide listing are the exact pattern that regulators have cited in enforcement actions.
Important notice: This article is provided for educational and informational purposes only. It does not constitute medical, legal, or regulatory advice. Research peptides discussed here are sold exclusively for laboratory research use and are not approved by the MHRA, the FDA, or any other regulatory agency for human or veterinary use. Nothing in this article should be construed as guidance for human consumption, dosing, or administration. Researchers are responsible for complying with all applicable laws and regulations in their jurisdiction. Always consult the product label, the certificate of analysis, and a qualified professional before making decisions about any substance.